- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06310551
Eerste keer in menselijke studie van langwerkende VH4524184-formuleringen
Een fase 1 dubbelblinde (sponsor-niet-geblindeerde), placebo-gecontroleerde, gerandomiseerde, enkelvoudige oplopende dosis en meervoudige dosisstudie om de veiligheid, verdraagbaarheid en farmacokinetiek van parenteraal toegediende VH4524184 bij gezonde volwassenen te onderzoeken
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Geneesmiddel: Oral VH4524184
- Geneesmiddel: VH4524184 Formulation A SC
- Geneesmiddel: Placebo Formulation A SC
- Geneesmiddel: rHuPH20
- Geneesmiddel: VH4524184 Formulation B SC
- Geneesmiddel: Placebo Formulation B SC
- Geneesmiddel: VH4524184 Formulation A IM
- Geneesmiddel: Placebo Formulation A IM
- Geneesmiddel: VH4524184 Formulation B IM
- Geneesmiddel: Placebo Formulation B IM
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Studie Contact Back-up
- Naam: EU GSK Clinical Trials Call Center
- Telefoonnummer: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Studie Locaties
-
-
Kansas
-
Lenexa, Kansas, Verenigde Staten, 66219
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Patrick Yao
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89113
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Aishwarya Vyas-Lahar
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78744
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Sean Gilbey
-
San Antonio, Texas, Verenigde Staten, 78232
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Robert Bass
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84124
- Werving
- GSK Investigational Site
-
Hoofdonderzoeker:
- Ahad Sabet
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Age
-Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
Type of Participant and Characteristics
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
Weight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive) for all cohorts except B19. For Cohort B19, body mass index within the range >32.0 to 37.0 kg/m^2 (inclusive).
Sex and Contraceptive/Barrier Requirements
-
Male or female
-
Male Participants: No restrictions for male participants
-
Participants of female sex assigned at birth:
- A participant of childbearing potential (POCBP) (female sex assigned at birth) is eligible to participate as long as the participant is not pregnant, breastfeeding and utilizes a highly effective method of contraception.
- A participant of non-childbearing potential (PONCBP) is eligible to participate if all other eligibility criteria are met.
Informed Consent
-
-
Capable of providing signed informed consent.
Exclusion Criteria:
Medical Conditions
- History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Clinically significant abnormal blood pressure as determined by the investigator.
- Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
- Breast cancer within the past 10 years.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities.
- Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome.
- Underlying skin disease or disorder that would interfere with the administration of study product and/or assessment of injection site reactions.
- Clinically significant history of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reactions, as well as history of /sensitivity to any of the study interventions including hyaluronidases.
- Current or anticipated need for chronic anti-coagulation except for the use of low dose acetylsalicylic acid (≤325 mg) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
- History of seizure.
- Any known or suspected pre-existing psychiatric condition, including depression, anxiety and insomnia/sleep disturbances, at the discretion of the investigator.
- Any positive (abnormal) response confirmed by the investigator or clinician (or qualified designee) administered C-SSRS at screening.
- Insufficient muscle mass (gluteus medius or thigh) to support IM dose administration in the opinion of the investigator.
- Presence of tattoos, implants or skin piercings that may interfere with the administration of study product and/or assessment of ISRs, if they occur.
- History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator. This includes participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.
Prior/Concomitant Therapy
- Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
- Receipt of any live vaccine(s) within 28 days prior to screening or 14 days before or after scheduled SC or IM dosing.
Prior/Concurrent Clinical Study Experience
- Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day.
- Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product before signing of consent (OR screening) any other clinical study.
- Participation in the study would result in loss of blood in excess of 500 mL over a 56-day period.
- Current enrollment or past participation in this clinical study, with the exception of participants who previously completed the Oral Lead In (OLI) but for operational or logistic reasons did not progress to CRU admission and receipt of injectable suspension for injection (SFI) or powder for suspension for injection (PFS) study medication or placebo, or prior participation in study 218803.
Diagnostic Assessments
- eGFR <60 mL/min or serum creatinine >1.1 x ULN.
- Hemoglobin <12.5 g/dL for men and <11 g/dL for women
- ALT or AST > upper limit of normal (ULN).
- Total bilirubin >1.5xULN.
- Any significant arrhythmia or ECG finding.
- Exclusion criteria for Screening ECG - a single repeat is allowed for eligibility determination.
- Presence of HBsAg and/or anti-HBc at Screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
- Positive pre-study drug/alcohol screen.
- Positive HIV antibody test.
Other Exclusions
- Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of >14 units for males or >7 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Regular use of known drugs of abuse.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening and at admission.
- Sensitivity to the study drug, or components thereof, or other drug or other allergy that, in the opinion of the investigator or Sponsor Medical Monitor, contraindicates participation in the study.
- Fasting glucose >125 mg/dL (6.95 mmol/L) or receiving treatment for elevated blood glucose.
- Triglycerides >500 mg/dL (5.7 mmol/L) or receiving treatment for dyslipidemia.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Formulation A SC Group
Participants receive a Formulation A starting dose of VH4524184 LAI subcutaneously (SC). |
VH4524184 to be taken orally. VH4524184 LAI Formulation A administered subcutaneously. Placebo Formulation A administered subcutaneously. rHuPH20 administered subcutaneously.
Andere namen:
|
|
Experimenteel: Formulation B SC Group
Participants receive a Formulation B starting dose of VH4524184 LAI subcutaneously (SC). |
VH4524184 to be taken orally. rHuPH20 administered subcutaneously.
Andere namen:
VH4524184 LAI Formulation B administered subcutaneously. Placebo Formulation B administered subcutaneously. |
|
Experimenteel: Formulation A IM Group
Participants receive a Formulation A starting dose of VH4524184 LAI intramuscularly (IM). |
VH4524184 to be taken orally. VH4524184 LAI Formulation A administered intramuscularly. Placebo Formulation A administered intramuscularly. |
|
Experimenteel: Formulation B IM Group
Participants receive a Formulation B starting dose of VH4524184 LAI intramuscularly (IM). |
VH4524184 to be taken orally. VH4524184 LAI Formulation B administered intramuscularly. Placebo Formulation B administered intramuscularly. |
|
Experimenteel: Multiple doses Group
VH4524184 LAI formulations administered SC or IM as single doses that achieve adequate PK exposure targets, may be evaluated for safety and tolerability as multiple doses. |
VH4524184 to be taken orally. VH4524184 LAI Formulation A administered subcutaneously. Placebo Formulation A administered subcutaneously. rHuPH20 administered subcutaneously.
Andere namen:
VH4524184 LAI Formulation B administered subcutaneously. Placebo Formulation B administered subcutaneously. VH4524184 LAI Formulation A administered intramuscularly. Placebo Formulation A administered intramuscularly. VH4524184 LAI Formulation B administered intramuscularly. Placebo Formulation B administered intramuscularly. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants discontinuing the treatment due to AEs
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Maximum toxicity grade increase from baseline in ALT, AST and alkaline phosphatase
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Maximum toxicity grade increase from baseline in total bilirubin
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Maximum toxicity grade increase from baseline in INR
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Duration of injection site reaction AEs
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity time (AUC[0-inf]) of LAI VH4524184 following single dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Area under the plasma drug concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-t]) of LAI VH4524184 following multiple dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Maximum observed plasma drug concentration (Cmax) of LAI VH4524184 following single dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Cmax of LAI VH4524184 following multiple dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Time to maximum observed plasma drug concentration (Tmax) of LAI VH4524184 following single dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Tmax of LAI VH4524184 following multiple dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Apparent terminal half-life (t1/2) of LAI VH4524184 following single dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
t1/2 of LAI VH4524184 following multiple dose administration
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
|
Percentage of participants reporting adverse events (AEs) and related AEs
Tijdsspanne: From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Related AE = AE assessed by the investigator as related to the study drug. |
From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
Percentage of participants with AEs by severity
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
Severity of AEs will be assessed using Division of AIDS Table for Grading the Severity of Adult Adverse Events (DAIDS). DAIDS grading scale is used to grade the toxicity associated with injection site reactions (ISR) including injection site pain (or tenderness), erythema (or redness), induration (or swelling), and pruritus. The toxicity level is graded from Grade 1 (lowest toxicity) to 4 (highest toxicity). Higher grade indicates higher toxicity. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
Change from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase parameters
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
The liver panel laboratory parameters are assessed after the administration of long-acting injectable (LAI) VH4524184. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
Change from baseline in total bilirubin parameters
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
The liver panel laboratory parameters are assessed after the administration of LAI VH4524184. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
Change from baseline in international normalized ratio (INR) parameters
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
The liver panel laboratory parameters are assessed after the administration of LAI VH4524184. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
|
Percentage of participants reporting injection site reaction (ISR) AEs
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life threatening. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities
Tijdsspanne: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
Grade 3 is defined as causing an inability to perform usual social & functional activities with intervention or hospitalization indicated. Grade 4 is defined as an abnormality that is potentially life-threatening, causing an inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death. |
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Door bloed overgedragen infecties
- Urogenitale ziekten
- Genitale ziekten
- Ziekten van het immuunsysteem
- Infecties
- RNA-virusinfecties
- Virusziekten
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- HIV-infecties
Andere studie-ID-nummers
- 218804
- NCT06310551 (Register-ID: ClinicalTrials.gov)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
IPD-tijdsbestek voor delen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-toegangscriteria voor delen
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .